Enhertu breast cancer drug now available on NHS England after delay

NHS England will now fund Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer, offering an average of seven months additional survival. The drug was already available in Scotland for over two years, highlighting a UK access disparity now resolved. This expands treatment options but does not change the overall cancer landscape.